ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $674,208 | +18.0% | 7,200 | +12.5% | 0.04% | +18.9% |
| Q2 2023 | $571,200 | -33.4% | 6,400 | -20.0% | 0.04% | -27.5% |
| Q1 2023 | $857,760 | -3.8% | 8,000 | +9.6% | 0.05% | +10.9% |
| Q4 2022 | $891,549 | +72.8% | 7,300 | +46.0% | 0.05% | +142.1% |
| Q3 2022 | $516,000 | +11.0% | 5,000 | -0.0% | 0.02% | +46.2% |
| Q2 2022 | $465,000 | +72.2% | 5,001 | +117.4% | 0.01% | +62.5% |
| Q1 2022 | $270,000 | -59.9% | 2,300 | -54.0% | 0.01% | -52.9% |
| Q4 2021 | $673,000 | +111.0% | 5,000 | +149.5% | 0.02% | +112.5% |
| Q3 2021 | $319,000 | +21.3% | 2,004 | +0.2% | 0.01% | 0.0% |
| Q2 2021 | $263,000 | -48.9% | 2,000 | -40.1% | 0.01% | -68.0% |
| Q3 2020 | $515,000 | – | 3,340 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |